Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement. Please note that this agreement limits use to scientific
  research. Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:59:54 ON 14 JAN 2008

=> file registry
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                         ENTRY   SESSION
FULL ESTIMATED COST   0.21   0.21

FILE 'REGISTRY' ENTERED AT 17:00:04 ON 14 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 JAN 2008 HIGHEST RN 960495-31-2
DICTIONARY FILE UPDATES: 13 JAN 2008 HIGHEST RN 960495-31-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10533152\10533152a.str





chain nodes :
16
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
4-16 9-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-16 5-6 5-7 6-9 7-8 8-9
exact bonds :
9-10
normalized bonds :
10-11 10-15 11-12 12-13 13-14 14-15

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 17:00:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      110 TO ITERATE

100.0% PROCESSED      110 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1571 TO     2829
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 17:00:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     2241 TO ITERATE

100.0% PROCESSED     2241 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

L3            1 SEA SSS FUL L1

=> d l3

L3   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   339566-10-8  REGISTRY
ED   Entered STN:  06 Jun 2001
CN   Imidazo[1,2-b]isoquinoline-5,10-dione, 3-phenyl-  (CA INDEX NAME)
MF   C17 H10 N2 O2
SR   Reaction Database
LC   STN Files:   CASREACT
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10533152\10533152b.str





chain nodes :
16
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
4-16 9-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-15 11-12 12-13 13-14
 14-15
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-16 5-6 5-7 6-9 7-8 8-9 9-10
normalized bonds :
10-11 10-15 11-12 12-13 13-14 14-15

G1:CH,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS

L4   STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4   STR



G1 CH,N

Structure attributes must be viewed using STN Express query preparation.

=> s l4
SAMPLE SEARCH INITIATED 17:02:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   264 TO ITERATE

100.0% PROCESSED   264 ITERATIONS   0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 4306 TO   6254
PROJECTED ANSWERS: 0 TO   0

L5   0 SEA SSS SAM L4

=> s l4 full
FULL SEARCH INITIATED 17:02:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   5294 TO ITERATE

100.0% PROCESSED   5294 ITERATIONS   0 ANSWERS
SEARCH TIME: 00.00.01

L6   0 SEA SSS FUL L4

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10533152\10533152c.str





chain nodes :
16
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
4-16 9-10
ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-15 11-12 12-13 13-14
 14-15
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-16 5-6 5-7 6-9 7-8 8-9 9-10
normalized bonds :
10-11 10-15 11-12 12-13 13-14 14-15

G1:CH,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS

L7   STRUCTURE UPLOADED

=> d l7
L7 HAS NO ANSWERS
L7   STR



G1 CH,N

Structure attributes must be viewed using STN Express query preparation.

=> s l7
SAMPLE SEARCH INITIATED 17:06:15 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   216 TO ITERATE

100.0% PROCESSED   216 ITERATIONS   0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 3439 TO   5201

PROJECTED ANSWERS: 0 TO 0

L8 0 SEA SSS SAM L7

=> s l7 full
FULL SEARCH INITIATED 17:06:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4324 TO ITERATE

100.0% PROCESSED 4324 ITERATIONS 35 ANSWERS
SEARCH TIME: 00.00.01

L9 35 SEA SSS FUL L7

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 540.76 540.97

FILE 'CAPLUS' ENTERED AT 17:06:26 ON 14 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 14 Jan 2008 VOL 148 ISS 3
FILE LAST UPDATED: 13 Jan 2008 (20080113/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l9
L10 3 L9

=> s l9 and pd<=20021106
  3 L9
 22840688 PD<=20021106
  (PD<=20021106)
L11 0 L9 AND PD<=20021106

=> d l10 1-3 ibib abs hitstr

L10 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:128501 CAPLUS
DOCUMENT NUMBER: 144:343043
TITLE: Imidazo[1,2-a]pyrazin-8-ones, imidazo[1,2-d][1,2,4]triazin-8-ones and imidazo[2,1-f][1,2,4]triazin-8-ones as α2/α3 subtype selective GABAA agonists for the treatment of anxiety
AUTHOR(S): Goodacre, Simon C.; Hallett, David J.; Carling, Robert W.; Castro, Jose L.; Reynolds, David S.; Pike, Andrew;

Wafford, Keith A.; Newman, Robert; Atack, John R.; Street, Leslie J.
CORPORATE SOURCE: Neuroscience Research Centre, Merck, Sharp and Dohme Research Laboratories, Harlow, Essex, CM20 2QR, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(6), 1582-1585
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:343043
AB Imidazo[1,2-a]pyrazin-8-ones, imidazo[1,2-d][1,2,4]triazin-8-ones and imidazo[2,1-f][1,2,4]triazin-8-ones are high affinity GABAA agonists. Compound 16d has good oral bioavailability in rat, functional selectivity for the GABAAα2 and α3-subtypes and is anxiolytic in a conditioned animal model of anxiety with minimal sedation observed at full BZ binding site occupancy.
IT 689296-91-1P 689297-04-9P 689297-17-4P
689297-19-6P 689297-55-0P 798570-60-2P
881743-79-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(α2/α3 subtype selective GABAA agonists for the treatment of anxiety)
RN 689296-91-1 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)



RN 689297-04-9 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)



RN 689297-17-4 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',6-difluoro- (CA INDEX NAME)



RN 689297-19-6 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)



RN 689297-55-0 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-d][1,2,4]triazin-3-yl)-2',4-difluoro- (CA INDEX NAME)



RN 798570-60-2 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(3,4-dihydro-3-methyl-4-oxoimidazo[2,1-f][1,2,4]triazin-7-yl)-2',4-difluoro- (CA INDEX NAME)



RN 881743-79-9 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-7,8-dihydro-8-oxoimidazo[1,2-d][1,2,4]triazin-3-yl)-2',4-difluoro- (CA INDEX NAME)



IT 881743-74-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α2/α3 subtype selective GABAA agonists for the treatment of anxiety)
RN 881743-74-4 CAPLUS
CN Imidazo[1,2-a]pyrazin-8(7H)-one, 7-methyl-3-phenyl- (CA INDEX NAME)



IT 689297-65-2P 689297-98-1P 918544-48-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(α2/α3 subtype selective GABAA agonists for the treatment of anxiety)
RN 689297-65-2 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)



RN 689297-98-1 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)



RN 918544-48-6 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',6-difluoro- (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1019775 CAPLUS
DOCUMENT NUMBER: 142:6561
TITLE: Preparation of imidazotriazinones as ligands for GABA receptors for treating anxiety, convulsions or cognitive disorders
INVENTOR(S): Goodacre, Simon Charles
PATENT ASSIGNEE(S): Merck Sharp & Dohme Ltd., UK
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004235844	A1	20041125	US 2004-848461	20040518
US 6914060	B2	20050705		
PRIORITY APPLN. INFO.:			GB 2003-11859 A	20030522
OTHER SOURCE(S):	MARPAT 142:6561			

GI



I

AB The title compds. [I; X1 = H, halo, alkyl, CF3, alkoxy; X2 = H, halo; Y = a bond, O, NH; Z = (un)substituted (hetero)aryl; R1 = alkyl, heterocyclyl, CF3, etc.], being ligands for GABAA receptors and accordingly of benefit in the therapy of deleterious neurol. disorders, were prepared E.g., a 5-step synthesis of 4,2'-difluoro-5'-(3-methyl-4-oxo-3,4-dihydroimidazo[2,1-f][1,2,4]triazin-7-yl)biphenyl-2-carbonitrile, starting from 4-methyl-3-thiosemicarbazide, which showed Ki of ≤ 100 nM for displacement of [3H]-flumazenil from the α2 and/or α3 and/or α5 subunit of the human GABAA receptor, was given. The pharmaceutical composition comprising the compound I is disclosed.

IT 798570-60-2P, 4,2'-Difluoro-5'-(3-methyl-4-oxo-3,4-dihydroimidazo[2,1-f][1,2,4]triazin-7-yl)biphenyl-2-carbonitrile
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazotriazinones as ligands for GABA receptors)

RN 798570-60-2 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(3,4-dihydro-3-methyl-4-oxoimidazo[2,1-f][1,2,4]triazin-7-yl)-2',4-difluoro- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:412949 CAPLUS

DOCUMENT NUMBER: 140:406827

TITLE: Preparation of imidazopyrazinone and imidazotriazinone derivatives as GABAA receptor ligands

INVENTOR(S): Carling, William Robert; Castro Pineiro, Jose Luis; Goodacre, Simon Charles; Hallett, David James; Street, Leslie Joseph

PATENT ASSIGNEE(S): Merck Sharp & Dohme Limited, UK

SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041826	A1	20040521	WO 2003-GB4685	20031029
WO 2004041826	A8	20050630		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003278377	A1	20040607	AU 2003-278377		20031029
US 2006014744	A1	20060119	US 2005-533152		20050427
PRIORITY APPLN. INFO.:			GB 2002-25923	A	20021106
			GB 2003-2529	A	20030204
			GB 2003-4415	A	20030226
			GB 2003-13646	A	20030612
			WO 2003-GB4685	W	20031029

OTHER SOURCE(S): MARPAT 140:406827
GI



I



II

AB The title compds. I [-U-V- = -CH=CH-, -CH2-CH2-, -N=CH-, or -CH=N-; X1 = H, halo, alkyl, CF3, or alkoxy; X2 = H or halo; Y = a bond, O, -NH-, -OCH2-; Z = (substituted)aryl or (substituted)heteroaryl; R1 = alkyl, heterocyclyl, CF3, -SO2Ra, -SO2NRaRb, -CORa, or -CONRaRb; Ra, Rb = H,

alkyl, heterocyclyl] were prepared as as GABAA receptor ligands for treating and/or preventing anxiety, convulsions or a cognitive disorder. Thus, reaction of 3-bromo-8-methoxyimidazo[1,2-a]pyrazine (preparation given) and 2'-fluoro-5'-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-biphenyl-2-carbonitrile following by heating in HBr and methylation afforded compound II.

IT 689296-91-1P 689296-94-4P 689296-98-8P
689297-01-6P 689297-04-9P 689297-07-2P
689297-10-7P 689297-13-0P 689297-15-2P
689297-17-4P 689297-19-6P 689297-21-0P
689297-23-2P 689297-25-4P 689297-27-6P
689297-29-8P 689297-31-2P 689297-33-4P
689297-35-6P 689297-37-8P 689297-39-0P
689297-41-4P 689297-43-6P 689297-45-8P
689297-47-0P 689297-49-2P 689297-51-6P
689297-53-8P 689297-55-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyrazinone and imidazotriazinone derivs. as GABAA receptor ligands)

RN 689296-91-1 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)



RN 689296-94-4 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)



RN 689296-98-8 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 2'-fluoro-5'-[7-(2-fluoroethyl)-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)



RN 689297-01-6 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7-(2,2-difluoroethyl)-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl]-2'-fluoro- (CA INDEX NAME)



RN 689297-04-9 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)



RN 689297-07-2 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 3'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-4'-fluoro- (CA INDEX NAME)



RN 689297-10-7 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 3'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-5'-fluoro- (CA INDEX NAME)



RN 689297-13-0 CAPLUS
CN [1,1'-Biphenyl]-4-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2,2'-difluoro- (CA INDEX NAME)



RN 689297-15-2 CAPLUS
CN Imidazo[1,2-a]pyrazin-8(7H)-one, 7-ethyl-3-[4-fluoro-3-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]phenyl]- (CA INDEX NAME)



RN 689297-17-4 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',6-difluoro- (CA INDEX NAME)



RN 689297-19-6 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)



RN 689297-21-0 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7-(2,2-difluoroethyl)-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl]-2',4-difluoro- (CA INDEX NAME)



RN 689297-23-2 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7,8-dihydro-7-(1-methylethyl)-8-oxoimidazo[1,2-a]pyrazin-3-yl]-2',4-difluoro- (CA INDEX NAME)



RN 689297-25-4 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 2',4-difluoro-5'-[7-(2-fluoroethyl)-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)



RN 689297-27-6 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7,8-dihydro-8-oxo-7-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyrazin-3-yl]-2',4-difluoro- (CA INDEX NAME)



RN 689297-29-8 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7,8-dihydro-7-[(1-methyl-1H-1,2,4-triazol-5-yl)methyl]-8-oxoimidazo[1,2-a]pyrazin-3-yl]-2',4-difluoro- (CA INDEX NAME)



RN 689297-31-2 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7,8-dihydro-8-oxo-7-(2-pyridinylmethyl)imidazo[1,2-a]pyrazin-3-yl]-2',4-difluoro- (CA INDEX NAME)



RN 689297-33-4 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',6-difluoro- (CA INDEX NAME)



RN 689297-35-6 CAPLUS
CN [1,1'-Biphenyl]-4-carbonitrile, 3-chloro-5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)



RN 689297-37-8 CAPLUS
CN Imidazo[1,2-a]pyrazin-8(7H)-one, 3-[4-fluoro-3-[(1-methyl-1H-1,2,3-triazol-4-yl)methoxy]phenyl]-7-methyl- (CA INDEX NAME)



RN 689297-39-0 CAPLUS
CN Imidazo[1,2-a]pyrazin-8(7H)-one, 3-[4-fluoro-3-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]phenyl]-7-methyl- (CA INDEX NAME)



RN 689297-41-4 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 2',4-difluoro-5'-(5,6,7,8-tetrahydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)- (CA INDEX NAME)



RN 689297-43-6 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 2',5-difluoro-5'-(5,6,7,8-tetrahydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)- (CA INDEX NAME)



RN 689297-45-8 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 2',6-difluoro-5'-(5,6,7,8-tetrahydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)- (CA INDEX NAME)



RN 689297-47-0 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-5,6,7,8-tetrahydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)



RN 689297-49-2 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-5,6,7,8-tetrahydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',5-difluoro- (CA INDEX NAME)



RN 689297-51-6 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-5,6,7,8-tetrahydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',6-difluoro- (CA INDEX NAME)



RN 689297-53-8 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 2',4-difluoro-5'-[5,6,7,8-tetrahydro-8-oxo-7-(2-pyridinylmethyl)imidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)



RN 689297-55-0 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-d][1,2,4]triazin-3-yl)-2',4-difluoro- (CA INDEX NAME)



IT 689297-65-2P 689297-98-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazopyrazinone and imidazotriazinone derivs. as GABAA receptor ligands)
RN 689297-65-2 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)



RN 689297-98-1 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)



=>
Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 3	OCT 19	BEILSTEIN updated with new compounds
NEWS 4	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 5	NOV 19	WPIX enhanced with XML display format
NEWS 6	NOV 30	ICSD reloaded with enhancements
NEWS 7	DEC 04	LINPADOCDB now available on STN
NEWS 8	DEC 14	BEILSTEIN pricing structure to change
NEWS 9	DEC 17	USPATOLD added to additional database clusters
NEWS 10	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 11	DEC 17	DGENE now includes more than 10 million sequences
NEWS 12	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 13	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 14	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 15	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 16	JAN 02	STN pricing information for 2008 now available
NEWS 17	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 18	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 19	JAN 28	MARPAT searching enhanced
NEWS 20	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 21	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 22	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 23	FEB 08	STN Express, Version 8.3, now available
NEWS 24	FEB 20	PCI now available as a replacement to DPCI

```
 NEWS 25  FEB 25  IFIREF reloaded with enhancements
 NEWS 26  FEB 25  IMSPRODUCT reloaded with enhancements
 NEWS 27  FEB 29  WPINDEX/WPIDS/WPIX enhanced with ECLA and current
                  U.S. National Patent Classification


 NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:38:55 ON 12 MAR 2008

=> gistry
GISTRY IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 16:39:04 ON 12 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   11 MAR 2008  HIGHEST RN 1007457-12-6
DICTIONARY FILE UPDATES:  11 MAR 2008  HIGHEST RN 1007457-12-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html
```

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10533152\10533152d.str



chain nodes :
10
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16
chain bonds :
4-10 9-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-12 11-16 12-13 13-14 14-15
 15-16
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-10 5-6 5-7 6-9 7-8 8-9
exact bonds :
9-11
normalized bonds :
11-12 11-16 12-13 13-14 14-15 15-16

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom

L1   STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1   STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 16:39:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      308 TO ITERATE

100.0% PROCESSED      308 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         5108 TO     7212
PROJECTED ANSWERS:               0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 16:39:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     6346 TO ITERATE

100.0% PROCESSED     6346 ITERATIONS                              45 ANSWERS
SEARCH TIME: 00.00.01

L3            45 SEA SSS FUL L1

=> d scan

L3   45 ANSWERS   REGISTRY  COPYRIGHT 2008 ACS on STN
IN   [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-
     a]pyrazin-3-yl)-2',6-difluoro-
MF   C20 H12 F2 N4 O
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.82	179.03

FILE 'CAPLUS' ENTERED AT 16:40:09 ON 12 MAR 2008

FILE COVERS 1907 - 12 Mar 2008 VOL 148 ISS 11
FILE LAST UPDATED: 11 Mar 2008 (20080311/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 8 L3

=> d l4 1-8 ibib abs hitstr

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:966023 CAPLUS
DOCUMENT NUMBER: 147:322989
TITLE: Preparation of bicyclic heteroaryl derivatives as cannabinoid receptor modulators
INVENTOR(S): Kundo, Mrinalkanti; Khairatkar-Joshi, Neelima; Nadkarni, Suhas M.; Pansare, Rameswar Madhavrao; Karnik, Pallavi V.
PATENT ASSIGNEE(S): Glenmark Pharmaceuticals S.A., Switz.
SOURCE: PCT Int. Appl., 172pp., which
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007096764	A2	20070830	WO 2007-IB459	20070226

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:		
IN 2006-MU275	A	20060227
US 2006-781055P	P	20060310
IN 2006-MU1146	A	20060718
US 2006-821475P	P	20060804
IN 2006-MU2088	A	20061220

OTHER SOURCE(S): MARPAT 147:322989
GI



I



II

AB Title compds. represented by the formula I [wherein X1 = CR, X2 = N or X1 = N, X2 = CR; R, R1a, R1b, R2, R3 = independently H, cyano, formyl, etc.; m = 1-5; n = 1-5; and analogs, N-oxides, tautomers, regioisomers, prodrugs, polymorphs, and pharmaceutically acceptable salts or solvates thereof] were prepared as cannabinoid receptor modulators. For example, reaction of (5-phenylpyrazin-2-yl)amine with 2-bromo-1-(4-chlorophenyl)-2-phenylethanone (preparation given) gave II. I were tested in in vitro for rat CB1 receptor binding using brain membrane and hCB1-CHO membranes, in vitro protocol for rat CB2 receptor binding using spleen membrane and hCB2-CHO

membranes. Thus, I and their pharmaceutical compns. are useful for the treatment of diseases, conditions and/or disorders modulated by a cannabinoid receptor, such as pain, neurodegenerative disorders, eating disorders, weight loss or control, obesity, smoking cessation, alc. dependency, depression, and attention deficit hyperactivity disorder.

IT 947592-97-4P, 2,3-Bis(4-chlorophenyl)-6-(3-chlorophenyl)-8-methoxyimidazo[1,2-a]pyrazine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazo[1,2-a]pyrazine and imidazo[1,2-a]pyrimidine derivs. as cannabinoid receptor modulators)

RN 947592-97-4 CAPLUS

CN Imidazo[1,2-a]pyrazine, 6-(3-chlorophenyl)-2,3-bis(4-chlorophenyl)-8-methoxy- (CA INDEX NAME)



L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:507532 CAPLUS

DOCUMENT NUMBER: 146:501082

TITLE: Imidazopyrazine compounds and their methods for inhibiting protein kinases, preparation, pharmaceutical compositions and use in the treatment of protein kinase-associated diseases

INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Parry, David A.; Zhao, Lianyun; Curran, Patrick J.; Belanger, David B.; Hamann, Blake; Reddy, Panduranga Adulla P.; Siddiqui, M. Arshad; Tadikonda, Praveen K.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 346pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007105864	A1	20070510	US 2006-598188	20061108
WO 2007056468	A1	20070518	WO 2006-US43512	20061108

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-735610P P 20051110
OTHER SOURCE(S): MARPAT 146:501082

GI



I



II

AB The invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, CHeckpoint kinase, Aurora kinase, Pim-1 kinase, and tyrosine kinase using imidazo[1,2-a]pyrazine compds. of formula I and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with protein kinases using such compds. Compds. of formula I wherein R is H, halo, (un)substituted (hetero)aryl, (un)substituted cycloalkyl, (un)substituted arylalkyl, (un)substituted heterocyclyl, etc.; R1 is H, halo, and alkyl; R2 is alkyl, (un)substituted (hetero)aryl(alkyl), alkenyl, alkynyl, etc.; R3 is H, (un)substituted (hetero)aryl(alkyl), (un)substituted heterocyclyl(alkyl), (un)substituted (hetero)cycloalkyl, etc.; and their pharmaceutically acceptable salts, solvates, esters, and prodrugs thereof are claimed. Example compound II was prepared by amination of 3-(1-methylpyrazol-4-yl)-7-methylsulfonylimidazo[1,2-a]pyrazine with 3-(methylsulfonyl)aniline. All the invention compds. were evaluated for their protein kinase inhibitory activity (data given).

IT 887476-05-3P 936360-38-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of imidazopyrazine compds. as protein kinase inhibitors useful in treatment and prevention of protein kinase-associated diseases)

RN 887476-05-3 CAPLUS

CN Benzenamine, 4-(6-bromo-8-methoxyimidazo[1,2-a]pyrazin-3-yl)-N,N-dimethyl- (CA INDEX NAME)



RN 936360-38-2 CAPLUS
CN Imidazo[1,2-a]pyrazine, 6-bromo-8-methoxy-3-(3-methyl-1H-indazol-5-yl)- (CA INDEX NAME)



L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:463553 CAPLUS
DOCUMENT NUMBER: 144:488677
TITLE: Preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Zhao, Lianyun; Curran, Patrick J.; Belanger, David B.; Hamann, Blake; Reddy, Panduranga A.; Siddiqui, M. Arshad
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 161 pp., Cont.-in-part of U.S. Ser. No. 47,524.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006106023	A1	20060518	US 2005-272392	20051110
US 2004063715	A1	20040401	US 2003-665005	20030919
US 6919341	B2	20050719		
US 2005130980	A1	20050616	US 2005-47524	20050131
WO 2007058873	A2	20070524	WO 2006-US43592	20061108
WO 2007058873	A3	20070719		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

AU 2007200401	A1	20070222	AU 2007-200401	20070131
PRIORITY APPLN. INFO.:			US 2002-412997P	P 20020923
			US 2003-665005	A3 20030919
			US 2005-47524	A2 20050131
			AU 2003-272476	A3 20030919
			US 2005-272392	A 20051110

OTHER SOURCE(S): MARPAT 144:488677

GI



I II

AB In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compds. of formula I [R = H, halo, (un)substituted-aryl, -heteroaryl, -cycloalkyl, etc.; R1 = H, halo or alkyl; R2 = halo, (un)substituted-alkyl, -aryl, -arylalkyl, etc.; R3 = H, (un)substituted-aryl, -heteroaryl, -heterocyclyl, etc.] as inhibitors of cyclin dependent kinases, methods of preparing such compds., pharmaceutical compns. containing one or more such compds., methods of preparing pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compds. or pharmaceutical compns. Thus, e.g., II was prepared by condensation of 8-chloro-3-methylimidazo[1,2-a]pyrazine with 4-(aminomethyl)pyridine. I possessed excellent CDK inhibitory properties, e.g., II demonstrated an IC50 value of 22.5 μM.

IT 887476-05-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors useful in treatment and prevention of various diseases)

RN 887476-05-3 CAPLUS

CN Benzenamine, 4-(6-bromo-8-methoxyimidazo[1,2-a]pyrazin-3-yl)-N,N-dimethyl- (CA INDEX NAME)



L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:128501 CAPLUS
DOCUMENT NUMBER: 144:343043
TITLE: Imidazo[1,2-a]pyrazin-8-ones, imidazo[1,2-d][1,2,4]triazin-8-ones and imidazo[2,1-f][1,2,4]triazin-8-ones as α2/α3 subtype selective GABAA agonists for the treatment of anxiety
AUTHOR(S): Goodacre, Simon C.; Hallett, David J.; Carling, Robert W.; Castro, Jose L.; Reynolds, David S.; Pike, Andrew; Wafford, Keith A.; Newman, Robert; Atack, John R.; Street, Leslie J.
CORPORATE SOURCE: Neuroscience Research Centre, Merck, Sharp and Dohme Research Laboratories, Harlow, Essex, CM20 2QR, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(6), 1582-1585
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:343043
AB Imidazo[1,2-a]pyrazin-8-ones, imidazo[1,2-d][1,2,4]triazin-8-ones and imidazo[2,1-f][1,2,4]triazin-8-ones are high affinity GABAA agonists. Compound 16d has good oral bioavailability in rat, functional selectivity for the GABAAα2 and α3-subtypes and is anxiolytic in a conditioned animal model of anxiety with minimal sedation observed at full BZ binding site occupancy.
IT 689296-91-1P 689297-04-9P 689297-17-4P 689297-19-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(α2/α3 subtype selective GABAA agonists for the treatment of anxiety)
RN 689296-91-1 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)



RN 689297-04-9 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)



RN 689297-17-4 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',6-difluoro- (CA INDEX NAME)



RN 689297-19-6 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)



IT 881743-74-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α2/α3 subtype selective GABAA agonists for the treatment of anxiety)
RN 881743-74-4 CAPLUS
CN Imidazo[1,2-a]pyrazin-8(7H)-one, 7-methyl-3-phenyl- (CA INDEX NAME)



IT 689297-63-0P 689297-65-2P 689297-98-1P
918544-48-6P 918545-23-0P 918545-44-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(α2/α3 subtype selective GABAA agonists for the treatment of anxiety)
RN 689297-63-0 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 2'-fluoro-5'-(8-methoxyimidazo[1,2-a]pyrazin-3-yl)- (CA INDEX NAME)



RN 689297-65-2 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)



RN 689297-98-1 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)



RN 918544-48-6 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',6-difluoro- (CA INDEX NAME)



RN 918545-23-0 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 2',4-difluoro-5'-(8-methoxyimidazo[1,2-a]pyrazin-3-yl)- (CA INDEX NAME)



RN 918545-44-5 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 2',6-difluoro-5'-(8-methoxyimidazo[1,2-a]pyrazin-3-yl)- (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:346791 CAPLUS
DOCUMENT NUMBER: 142:411376
TITLE: A preparation of imidazopyrazine derivatives, useful as antiarrhythmics
INVENTOR(S): Plouvier, Bertrand M. C.; Fedida, David; Beatch, Gregory N.; Chou, Doug Ta Hung; Yifru, Aregahegn S.; Jung, Grace
PATENT ASSIGNEE(S): Cardiome Pharma Corporation, Can.
SOURCE: PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005034837	A2	20050421	WO 2004-IB3601	20041008
WO 2005034837	A3	20050714		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-510010P P 20031008
OTHER SOURCE(S): CASREACT 142:411376; MARPAT 142:411376

GI



I



II



III

AB The invention relates to a preparation of imidazopyrazine derivs. of formula I [wherein: R1, R2, R3, and R4 are independently selected from H, Br, Cl, F, NO2, CHF2, or (cyclo)alkyl, etc.; R5 is a substituted alkyl], useful as antiarrhythmics. For instance, imidazopyrazinone derivative II [IC50 (μM), ion-channels: Kv1.5 - 4.8, hERG - 100, H1Na - 340, Kv2.1 - 60] was prepared via amination of 1-phenyl-1-cyclopropylmethanol by imidazopyrazine derivative III with a yield of 42%.

IT 850406-59-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyrazine derivs. useful as antiarrhythmics)

RN 850406-59-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-8(7H)-one, 5-chloro-7-[(2-nitrophenyl)methyl]-3-phenyl- (CA INDEX NAME)



L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:412949 CAPLUS

DOCUMENT NUMBER: 140:406827

TITLE: Preparation of imidazopyrazinone and imidazotriazinone derivatives as GABAA receptor ligands

INVENTOR(S): Carling, William Robert; Castro Pineiro, Jose Luis; Goodacre, Simon Charles; Hallett, David James; Street, Leslie Joseph

PATENT ASSIGNEE(S): Merck Sharp & Dohme Limited, UK

SOURCE: PCT Int. Appl., 49 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041826	A1	20040521	WO 2003-GB4685	20031029
WO 2004041826	A8	20050630		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003278377	A1	20040607	AU 2003-278377		20031029
US 2006014744	A1	20060119	US 2005-533152		20050427

PRIORITY APPLN. INFO.:

GB 2002-25923	A	20021106
GB 2003-2529	A	20030204
GB 2003-4415	A	20030226
GB 2003-13646	A	20030612
WO 2003-GB4685	W	20031029

OTHER SOURCE(S): MARPAT 140:406827

GI



I



II

AB The title compds. I [-U-V- = -CH=CH-, -CH2-CH2-, -N=CH-, or -CH=N-; X1 =

H, halo, alkyl, CF3, or alkoxy; X2 = H or halo; Y = a bond, O, -NH-, -OCH2-; Z = (substituted)aryl or (substituted)heteroaryl; R1 = alkyl, heterocyclyl, CF3, -SO2Ra, -SO2NRaRb, -CORa, or -CONRaRb; Ra, Rb = H, alkyl, heterocyclyl] were prepared as as GABAA receptor ligands for treating and/or preventing anxiety, convulsions or a cognitive disorder. Thus, reaction of 3-bromo-8-methoxyimidazo[1,2-a]pyrazine (preparation given) and 2'-fluoro-5'-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-biphenyl-2-carbonitrile following by heating in HBr and methylation afforded compound II.

IT 689296-91-1P 689296-94-4P 689296-98-8P
689297-01-6P 689297-04-9P 689297-07-2P
689297-10-7P 689297-13-0P 689297-15-2P
689297-17-4P 689297-19-6P 689297-21-0P
689297-23-2P 689297-25-4P 689297-27-6P
689297-29-8P 689297-31-2P 689297-33-4P
689297-35-6P 689297-37-8P 689297-39-0P
689297-41-4P 689297-43-6P 689297-45-8P
689297-47-0P 689297-49-2P 689297-51-6P
689297-53-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyrazinone and imidazotriazinone derivs. as GABAA receptor ligands)

RN 689296-91-1 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)



RN 689296-94-4 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)



RN 689296-98-8 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 2'-fluoro-5'-[7-(2-fluoroethyl)-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)



RN 689297-01-6 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7-(2,2-difluoroethyl)-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl]-2'-fluoro- (CA INDEX NAME)



RN 689297-04-9 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)



RN 689297-07-2 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 3'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-4'-fluoro- (CA INDEX NAME)



RN 689297-10-7 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 3'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-5'-fluoro- (CA INDEX NAME)



RN 689297-13-0 CAPLUS
CN [1,1'-Biphenyl]-4-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2,2'-difluoro- (CA INDEX NAME)



RN 689297-15-2 CAPLUS
CN Imidazo[1,2-a]pyrazin-8(7H)-one, 7-ethyl-3-[4-fluoro-3-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]phenyl]- (CA INDEX NAME)



RN 689297-17-4 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',6-difluoro- (CA INDEX NAME)



RN 689297-19-6 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)



RN 689297-21-0 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7-(2,2-difluoroethyl)-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl]-2',4-difluoro- (CA INDEX NAME)



RN 689297-23-2 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7,8-dihydro-7-(1-methylethyl)-8-oxoimidazo[1,2-a]pyrazin-3-yl]-2',4-difluoro- (CA INDEX NAME)



RN 689297-25-4 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 2',4-difluoro-5'-[7-(2-fluoroethyl)-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)



RN 689297-27-6 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7,8-dihydro-8-oxo-7-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyrazin-3-yl]-2',4-difluoro- (CA INDEX NAME)



RN 689297-29-8 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7,8-dihydro-7-[(1-methyl-1H-1,2,4-triazol-5-yl)methyl]-8-oxoimidazo[1,2-a]pyrazin-3-yl]-2',4-difluoro- (CA INDEX NAME)



RN 689297-31-2 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7,8-dihydro-8-oxo-7-(2-pyridinylmethyl)imidazo[1,2-a]pyrazin-3-yl]-2',4-difluoro- (CA INDEX NAME)



RN 689297-33-4 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',6-difluoro- (CA INDEX NAME)



RN 689297-35-6 CAPLUS
CN [1,1'-Biphenyl]-4-carbonitrile, 3-chloro-5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)



RN 689297-37-8 CAPLUS
CN Imidazo[1,2-a]pyrazin-8(7H)-one, 3-[4-fluoro-3-[(1-methyl-1H-1,2,3-triazol-4-yl)methoxy]phenyl]-7-methyl- (CA INDEX NAME)



RN 689297-39-0 CAPLUS
CN Imidazo[1,2-a]pyrazin-8(7H)-one, 3-[4-fluoro-3-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]phenyl]-7-methyl- (CA INDEX NAME)



RN 689297-41-4 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 2',4-difluoro-5'-(5,6,7,8-tetrahydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)- (CA INDEX NAME)



RN 689297-43-6 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 2',5-difluoro-5'-(5,6,7,8-tetrahydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)- (CA INDEX NAME)



RN 689297-45-8 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 2',6-difluoro-5'-(5,6,7,8-tetrahydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)- (CA INDEX NAME)



RN 689297-47-0 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-5,6,7,8-tetrahydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)



RN 689297-49-2 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-5,6,7,8-tetrahydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',5-difluoro- (CA INDEX NAME)



RN 689297-51-6 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-5,6,7,8-tetrahydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',6-difluoro- (CA INDEX NAME)



RN 689297-53-8 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 2',4-difluoro-5'-[5,6,7,8-tetrahydro-8-oxo-7-(2-pyridinylmethyl)imidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)



IT 689297-63-0P 689297-65-2P 689297-98-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazopyrazinone and imidazotriazinone derivs. as GABAA receptor ligands)
RN 689297-63-0 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 2'-fluoro-5'-(8-methoxyimidazo[1,2-a]pyrazin-3-yl)- (CA INDEX NAME)



RN 689297-65-2 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)



RN 689297-98-1 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)



L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:647967 CAPLUS
DOCUMENT NUMBER: 123:55918
TITLE: Preparation of 4-oxoimidazolo[1,2-a]quinoxalines as antagonists of excitatory amino acids.
INVENTOR(S): Treiber, Hans-Joerg; Behl, Berthold; Hofmann, Hans Peter
PATENT ASSIGNEE(S): BASF A.-G., Germany
SOURCE: Ger. Offen., 15 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4329970	A1	19941006	DE 1993-4329970	19930904
CA 2158167	A1	19941013	CA 1994-2158167	19940319
WO 9422865	A1	19941013	WO 1994-EP871	19940319
W: AU, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, NO, NZ, PL, RU, SI, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9464282	A	19941024	AU 1994-64282	19940319
BR 9406034	A	19960102	BR 1994-6034	19940319
EP 691970	A1	19960117	EP 1994-911932	19940319
EP 691970	B1	19981111		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1120336	A	19960410	CN 1994-191613	19940319
CN 1041928	B	19990203		
JP 08508271	T	19960903	JP 1994-521617	19940319
HU 73970	A2	19961028	HU 1995-2848	19940319
AT 173263	T	19981115	AT 1994-911932	19940319
IL 109076	A	19970610	IL 1994-109076	19940322
ZA 9402246	A	19951002	ZA 1994-2246	19940330
FI 9504614	A	19950928	FI 1995-4614	19950928
NO 9503892	A	19950929	NO 1995-3892	19950929

PRIORITY APPLN. INFO.:	DE 1993-4310521	A1	19930331
	DE 1993-4329970	A	19930904
	WO 1994-EP871	W	19940319

OTHER SOURCE(S): MARPAT 123:55918
GI



I

AB Title compds. [I; A = (unsatd.) C1-5 alkylene, bond; R1-R4 = H, F, Cl, Br, CF3, OCF3, cyano, NO2, amino, alkyl, alkoxy, alkylamino, alkylthio, alkylsulfenyl, alkylsulfonyl, aminosulfonyl, alkoxycarbonyl, etc.; R5 = H, alkyl, (substituted) Ph; R6 = CHO, (salt of) CO2H, CO2R7, hydroxyalkyl, alkylcarbonyl, cyano, tetrazolyl, aldoxime, carbamoyl, etc.; R7 = alkyl, cycloalkyl, PhCH2, etc.; with provisos], were prepared as antagonists of excitatory amino acids (no data). Thus, 1-(2-aminophenyl)4-carboethoxy-5-methylimidazole was refluxed 1.5 h with carbonyldiimidazole in 1,2-dichlorobenzene to give Et 4,5-dihydro-1-methyl-4-oxoimidazolo[1,2-a]quinoxalin-2-carboxylate. Tablets were prepared containing 4,5-dihydro-1-methyl-7-trifluoromethyl-4-oxoimidazolo[1,2-a]quinoxalin-2-carboxylic acid.

IT 164329-62-8P 164329-68-4P 164329-98-0P
164330-04-5P 164330-31-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-oxoimidazolo[1,2-a]quinoxalines as antagonists of excitatory amino acids)

RN 164329-62-8 CAPLUS

CN Imidazo[1,2-a]quinoxaline-2-carboxylic acid, 4,5-dihydro-4-oxo-1-phenyl-7-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)



RN 164329-68-4 CAPLUS

CN Imidazo[1,2-a]quinoxaline-2-propanoic acid, 4,5-dihydro-4-oxo-1-phenyl-7-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)



RN 164329-98-0 CAPLUS
CN Imidazo[1,2-a]quinoxaline-2-carboxylic acid, 4,5-dihydro-4-oxo-1-phenyl-7-(trifluoromethyl)- (CA INDEX NAME)



RN 164330-04-5 CAPLUS
CN Imidazo[1,2-a]quinoxaline-2-propanoic acid, 4,5-dihydro-4-oxo-1-phenyl-7-(trifluoromethyl)- (CA INDEX NAME)



RN 164330-31-8 CAPLUS
CN Imidazo[1,2-a]quinoxaline-2-propanoic acid, 8-chloro-4,5-dihydro-4-oxo-1-phenyl-7-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)



L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1959:72555 CAPLUS
DOCUMENT NUMBER: 53:72555
ORIGINAL REFERENCE NO.: 53:13139i,13140a-i,13141a-f
TITLE: Studies in the azole series. VII. Reactions of imidazoles with isocyanates
AUTHOR(S): Gompper, Rudolf; Hoyer, Ernst; Herlinger, Heinz
CORPORATE SOURCE: Tech. Hochschule, Stuttgart, Germany
SOURCE: Chemische Berichte (1959), 92, 550-63
CODEN: CHBEAM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB cf. C.A. 51, 13853i. 4,5-Disubstituted imidazoles containing at least 1 aryl group yield with boiling PhNCO in addition to the 4,5-disubstituted imidazole-2-carboxanilides and (PhNH)2CO (I) also 2-phenylimidazo[1,2-c]hydantoins which fluoresce in the solid state yellow to red depending on their color. Imidazoles react with aryl isocyanates in boiling PhNO2 to yield imidazole-2-carboxylic acid N-arylamides. The reaction mechanisms, the ultraviolet absorption, fluorescence, and infrared spectra of the various compds. are discussed. 4,5-Diphenylimidazole (II) (44 g.) and 250 cc. PhNCO refluxed 28 hrs., the excess PhNCO distilled in vacuo up to 170°, the yellow, resinous residue digested with C6H6, and the crystalline product recrystd. from 1:1 CHCl3-EtOAc yielded 31.5 g. anilide (III) of the 2-CO2H derivative (IV) of II, needles, m. 221-2°; the mother liquor deposited slowly 5 g. I, m. 240-2°; the C6H6 extract evaporated in vacuo, the semisolid residue digested with 400 cc. 1:1 MeOH-Et2O and filtered, and the filtrate evaporated gave 6 g. I; the filter residue recrystd. (EtOAc and then BuOH) gave 18.5 g. 2,5,6-triphenylimidazo[1,2-c]hydantoin (V), brilliant yellow needles, m. 207-8°. V (200 mg.) and 3 cc. PhNH2 refluxed 15 min., cooled 1 hr. to room temperature, and filtered yielded 95 mg. I; the mother liquor evaporated yielded 97 mg. III. V (17 g.), 132 g. KOH, 800 cc. MeOH, and 132 cc. H2O refluxed 0.5 hr., cooled overnight, and filtered, the residue dissolved in 300 cc. hot 15% HCl, the solution cooled, basified with aqueous NH4OH, and filtered, and the residue dissolved in hot glacial AcOH and stirred into H2O precipitated 6 g. IV, needles, m. 143-4° (decomposition) (30% aqueous EtOH). IV (1 g.) in 100 cc. absolute EtOH saturated with dry HCl, kept 3 days, poured into H2O, basified with NH4OH, and filtered gave 0.8 g. Et ester of IV, m. 197-200° (30% aqueous EtOH). IV (1.5 g.) refluxed 6 hrs. with 30 cc. SOCl2, kept overnight, and filtered gave 0.6 g. 2,3,7,8-tetraphenyl-5,10-dioxodiimidazo[1,2-a;1',2'-d]piperazine (VI), yellow crystals, did not melt below 350° (PhNO2). VI (55 mg.) and 0.7 cc. PhNH2 heated 10 min., kept overnight, and the precipitate filtered off gave 60 mg. III. II (11 g.) in 100 cc. dry PhNO2 treated at 130° dropwise during 10 min. with 10 g. PhNCO and 10 cc. PhNO2, refluxed 9 hrs., and cooled gave 13.8 g. III, needles, m. 221-2° (EtOH). III (3.4 g.) and 2.6 g. Me2SO4 in 20 cc. PhNO2 heated 6 hrs. on the H2O bath, cooled, diluted with 250 cc. Et2O, and filtered, the residue shaken with a mixture of 100 cc. CHCl3 and 100 cc. 20% aqueous NaOH, and the CHCl3 layer worked up gave 1.8 g. 1-Me derivative (VII) of III, needles, m. 197-9° (EtOH). 1-Methyl-4,5-diphenylimidazole (8 g.) and 100 cc. PhNCO refluxed 16 hrs., the excess PhNCO distilled in vacuo, and the residue digested with EtOAc, filtered off, and recrystd. (EtOH) yielded 8.2 g. VII. 4(5)-Methyl-5(4)-phenylimidazole (VIII) (20 g.) and 170 cc. PhNCO refluxed 24 hrs., stored overnight, and filtered yielded 7 g. 5(6)-methyl-2,6(5)-diphenylimidazo[1,2-c]hydantoin (IX). pale yellow leaflets, m. 239-41° (BuOH). Et analog (8 g.) of VIII and 45 cc. PhNCO refluxed 20 hrs., the excess PhNCO distilled in vacuo, the residue dissolved in C6H6 and the solution filtered, the filtrate evaporated in vacuo, and the residue dissolved in EtOAc and allowed to evaporate in air gave 2.5 g. 5(6)-Et analog of IX, yellowish needles, m. 198-9° (BuOH).

p-Chlorobenzoin (20 g.) and 100 cc. HCONH2 refluxed 4 hrs., kept overnight, and filtered, and the residue recrystd. [CH2(CO2Et)2] yielded 13 g. 4(5)-phenyl-5(4)-(p-chlorophenyl)imidazole (XI), m. 238-40°. XI (10 g.) and 50 cc. PhNCO refluxed 22 hrs., the excess PhNCO distilled in vacuo, and the residue digested with C6H6, filtered off, and recrystd. (C6H6) yielded 6 g. 2-CONHPh derivative (XII) of XI, m. 192-4°; the C6H6 solution evaporated and the residue crystallized from EtOAc gave 1.2 g. 2,5(6)-diphenyl-6(5)-(p-chlorophenyl)imidazo[1,2-c]hydantoin (XIII), m. 226-8° (BuOH). p-Bromobenzoin (17 g.) and 100 cc. HCONH2 refluxed 4 hrs. and cooled, and the crude product recrystd. [CH2(CO2Et)2] yielded 9.2 g. p-Br analog (XIV) of XI, m. 240-2°. XIV (6 g.) and 50 cc. PhNCO heated 20 hrs. and evaporated, and the residue digested with 180 cc. C6H6 left 1.5 g. p-Br analog of XII, needles, m. 181-3° (cyclohexane); the filtrate evaporated, the residue dissolved in EtOAc, the solution evaporated in air, the residue digested with iso-Pr2O, and the crude solid material recrystd. (BuOH) yielded 800 mg. p-Br analog of XIII, greenish yellow needles, m. 223-4°. 4(5)-Phenyl-5(4)-(p-dimethylaminophenyl)imidazole (15 g.) and 100 cc. PhNCO heated 23 hrs. and evaporated, and the residue digested with C6H6, filtered off. washed with C6H6, and recrystd. from PhMe yielded 8 g. p-Me2N analog of XII, needles, m. 208-9°; the C6H6 filtrate evaporated and the residue crystallized (EtOAc) yielded 5.3 g. p-Me2N analog of XIII, brilliant red needles, m. 232-4° (BuOH). 1-Et derivative (XV) (4.3 g.) of II and 50 cc. PhNCO refluxed 16 hrs., the excess PhNCO evaporated in vacuo, the residue dissolved in 30 cc. EtOAc, the solution filtered, and the filtrate evaporated gave 3.5 g.
2-CONHPh derivative of XV, leaflets, m. 141-3° (EtOH). II (20 g.) and 100 g. PhCH2Br heated 24 hrs. on the H2O bath and evaporated in vacuo, the resinous residue shaken with 250 cc. 20% aqueous NaOH and 200 cc. CHCl3, the CHCl3 layer evaporated, the residue dissolved in hot EtOH, the hot solution diluted
with hot H2O to incipient turbidity, cooled, and filtered, the filtrate diluted further with H2O, the tacky precipitate dissolved in CHCl3, and the solution
diluted with Et2O to turbidity and refrigerated several days gave 3.6 g. 4,5-diphenyl-1,3-dibenzyl-imidazolium bromide (XVI), leaflets, m. 211-13° [CH2(CO2Et)2]. XVI (3 g.) and 30 cc. PhNCO refluxed 16 hrs. and evaporated gave 2.1 g. 1-PhCH2 derivative of III, needles, m. 160-1° (EtOAc); also obtained from the 1-PhCH2 derivative of II with PhNCO. II (7 g.) and 5 g. p-O2NC6H4NCO refluxed 6 hrs. in 50 cc. PhNO2, cooled overnight, and filtered yielded 9 g. p-nitroanilide of IV, yellow leaflets, m. 316-19° (PhNO2). II (4.4 g.) dissolved in 40 cc. PhNO2 at 100°, treated during 10 min. dropwise with 5 g. 1-C10H7NCO (XVII), refluxed 6 hrs., stored 3 days, and filtered yielded 5.8 g. 1-naphthylamide (XVIII) of IV, needles, m. 239-41° (1:1 CHCl3EtOAc). 1-Me derivative (3 g.) of II and 5 g. XVII in 50 cc. PhNO2 refluxed 6 hrs. and evaporated gave 2.9 g. 1-Me derivative of XVIII, needles, m.
180-1° (EtOH). 3-Phenylindole (5 g.) and 50 cc. PhNCO refluxed 20 hrs. and evaporated in vacuo, and the residue digested with C6H6 and the solution
filtered gave 6 g. 3-phenylindole-2-carboxanilide, needles, m. 116-18° (EtOH or cyclohexane). 2,4-Diphenylpyrrole (4.4 g.) and 40 cc. PhNCO refluxed 20 hrs. and evaporated in vacuo gave 3.8 g. yellow needles, m. 165° (C6H6), apparently containing a hydantoin ring.
2-Methyl-4(5)-phenylimidazole (XIX) (5 g.) and 7.5 cc. PhNCO refluxed 9 hrs. in 65 cc. PhNO2, cooled, and filtered gave 4 g. 5(4)-CONHPh derivative of XIX, needles, m. 240-2° (decomposition) (EtOH). Benzimidazole (6 g.) and 10 cc. PhNCO in 100 cc. PhNO2 refluxed 5 hrs. and worked up in the usual manner yielded 5.5 g. benzimidazole-2-carboxanilide, needles, m. 235-6°. Theophylline (20 g.) and 36 g. PhNCO refluxed to solution, cooled, and filtered, and the residue boiled briefly with EtOH yielded 30

g. theophylline-7(9)-carboxanilide, m. 208° with gas evolution at 215-18°, resolidified at 220°, and remelted at 265° (theophylline). II (2 g.) and 3.5 cc. PhNCO allowed to stand 12 hrs. and filtered, and the residue washed with C6H6 gave 3 g. 1-CONHPh derivative of II, m. partially at about 115° (decomposition) (melt clear at 230°); the attempted recrystn. from C6H6 or PhMe gave only II. The ultraviolet, fluorescence, and infrared absorption maximum of the various compds. are tabulated.

IT 119925-84-7P, 5H,10H-Diimidazo[1,2-a:1',2'-d]pyrazine-5,10-dione, 2,3,7,8-tetraphenyl-
RL: PREP (Preparation)
(preparation of)

RN 119925-84-7 CAPLUS

CN 5H,10H-Diimidazo[1,2-a:1',2'-d]pyrazine-5,10-dione, 2,3,7,8-tetraphenyl- (CA INDEX NAME)



=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	47.44	226.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.40	-6.40

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:45:04 ON 12 MAR 2008